Can we cure the price problem for new cancer technologies?
Field | Value | Language |
dc.contributor.author | Sullivan, Richard | |
dc.date.accessioned | 2017-10-26 | |
dc.date.available | 2017-10-26 | |
dc.date.issued | 2017-10-26 | |
dc.identifier.uri | http://hdl.handle.net/2123/17325 | |
dc.description | Seminar presentation + oral recording | en_AU |
dc.description.abstract | In this lecture we will explore the evidence for the divergences and deficits, investor policy towards pricing and what determines price (such as power relationships), the conflicted relationship between the research communities, patient organisations, the media, regulatory authorities and pharmaceutical sector, and the data around declining value and affordability. What solutions can and should be imposed at both national and supra-national levels? | en_AU |
dc.description.sponsorship | Cancer Council Australia | en_AU |
dc.language.iso | en_AU | en_AU |
dc.subject | cancer | en_AU |
dc.subject | systems of care | en_AU |
dc.subject | outcomes | en_AU |
dc.subject | healthcare | en_AU |
dc.subject | medicine | en_AU |
dc.subject | new technology | en_AU |
dc.title | Can we cure the price problem for new cancer technologies? | en_AU |
dc.type | Presentation | en_AU |
dc.contributor.department | Menzies Centre for Health Policy | en_AU |
Associated file/s
Associated collections